SPY453.12-0.47 -0.10%
DIA356.74+0.78 0.22%
IXIC15,090.20-125.50 -0.82%

RBC Capital Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $6

RBC Capital analyst Gregory Renza initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Outperform rating and announces Price Target of $6.

Benzinga · 09/24/2021 07:22
RBC Capital analyst Gregory Renza initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Outperform rating and announces Price Target of $6.